| Host |
Mouse |
| Klon |
4C7 |
| Format |
ready-to-use |
| Methode |
F, P |
| Vorbehandlung |
Pepsin |
| Positivkontrolle |
Skin |
| Verdünnung |
- |
| Isotyp |
Mouse IgG2a |
| Lokalisation |
Basement Membrane |
Laminin
|
Diagnostic Biosystems |
4C7 |
6 ml |
ready-to-use |
CE/IVD |
PDM568 |
-
|
| Host |
Mouse |
| Klon |
450-30A |
| Format |
Purified |
| Methode |
F, FL |
| Isotyp |
Mouse IgG1 |
| Verdünnung |
Alpha 6 beta 4 integrin purified from A431 cells |
Laminin Receptor (CD49f, Integrin alpha6)
|
Zytomed Systems GmbH |
450-30A |
100 µg |
Purified |
RUO |
612-0058 |
-
|
| Host |
Rat |
| Klon |
NKI-GoH3 |
| Format |
Purified |
| Methode |
F, IP, FL |
| Isotyp |
Rat IgG2a |
| Verdünnung |
BALB/c mouse mammary tumour cells |
Laminin Receptor (CD49f, Integrin alpha6)
|
Zytomed Systems GmbH |
NKI-GoH3 |
100 µg |
Purified |
RUO |
612-0061 |
-
|
| Host |
Rabbit |
| Klon |
ZR170 |
| Format |
concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
skin/Langerhans cell histiocytosis |
| Verdünnung |
1:100-200 |
| Isotyp |
IgG |
| Verdünnung |
Recombinant fragment (around aa50-250) of human Langerin protein |
| Lokalisation |
Cell Surface and cytoplasmic |
Langerin
|
Zeta Corporation |
ZR170 |
0.5 ml |
concentrate |
RUO |
Z2700RS-R |
-
|
| Host |
Rabbit |
| Klon |
ZR336 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Chronic lymphocytic leukemia or small lymphocytic lymphoma |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG |
| Verdünnung |
Fragment (around aa 100-200) of human LEF1 protein |
| Lokalisation |
Nucleus |
LEF1
|
Zeta Corporation |
ZR336 |
1 ml |
Concentrate |
CE/IVD |
Z2642RL |
-
|
| Host |
Rabbit |
| Klon |
ZR336 |
| Format |
Ready-to-use |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Chronic lymphocytic leukemia or small lymphocytic lymphoma |
| Verdünnung |
- |
| Isotyp |
IgG |
| Verdünnung |
Fragment (around aa 100-200) of human LEF1 protein |
| Lokalisation |
Nucleus |
LEF1
|
Zeta Corporation |
ZR336 |
7 ml |
Ready-to-use |
CE/IVD |
Z2642RP |
-
|
| Host |
Rabbit |
| Klon |
ZR336 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Chronic lymphocytic leukemia or small lymphocytic lymphoma |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG |
| Verdünnung |
Fragment (around aa 100-200) of human LEF1 protein |
| Lokalisation |
Nucleus |
LEF1
|
Zeta Corporation |
ZR336 |
0.5 ml |
Concentrate |
CE/IVD |
Z2642RS |
-
|
| Host |
Rabbit |
| Klon |
ZR336 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Chronic lymphocytic leukemia or small lymphocytic lymphoma |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG |
| Verdünnung |
Fragment (around aa 100-200) of human LEF1 protein |
| Lokalisation |
Nucleus |
LEF1
|
Zeta Corporation |
ZR336 |
0.1 ml |
Concentrate |
CE/IVD |
Z2642RT |
-
|
| Host |
Mouse |
| Klon |
CA7AE |
| Format |
Lyophilised |
| Methode |
IF, EL, WB |
| Isotyp |
Mouse IgM |
| Verdünnung |
Heat killed L. donovani promastigotes |
Leishmania (LPG Repeat Epitope)
|
Zytomed Systems GmbH |
CA7AE |
0.5 ml |
Lyophilised |
RUO |
612-0093 |
-
|
| Host |
Mouse |
| Klon |
96/26 |
| Format |
Lyophilised |
| Methode |
IF, EL |
| Isotyp |
Mouse IgG2a |
| Verdünnung |
Recombinant Baculovirus expressed L. major p63 |
Leishmania (Major Surface Protease GP-63)
|
Zytomed Systems GmbH |
96/26 |
0.5 ml |
Lyophilised |
RUO |
612-0094 |
-
|
| Host |
Goat |
| Klon |
polyclonal |
| Format |
Purified |
| Methode |
EL, WB |
| Isotyp |
Goat IgG |
| Verdünnung |
Peptide sequence C-TQDDIEKHQSDAG from the internal region of leptin receptor (NP-002294.2, NP-001003679.1, NP-001003680.1) |
Leptin Receptor
|
Zytomed Systems GmbH |
polyclonal |
100 µg |
Purified |
RUO |
612-0191 |
-
|
| Host |
Rabbit |
| Klon |
ZR173 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Pituitary |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG |
| Verdünnung |
Recombinant full-length human LHB protein |
| Lokalisation |
Cytoplasm, secreted |
LH
|
Zeta Corporation |
ZR173 |
1 ml |
Concentrate |
CE/IVD |
Z2701RL |
-
|
| Host |
Rabbit |
| Klon |
ZR173 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Pituitary |
| Verdünnung |
- |
| Isotyp |
IgG |
| Verdünnung |
Recombinant full-length human LHB protein |
| Lokalisation |
Cytoplasm, secreted |
LH
|
Zeta Corporation |
ZR173 |
7 ml |
Concentrate |
CE/IVD |
Z2701RP |
-
|
| Host |
Rabbit |
| Klon |
ZR173 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Pituitary |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG |
| Verdünnung |
Recombinant full-length human LHB protein |
| Lokalisation |
Cytoplasm, secreted |
LH
|
Zeta Corporation |
ZR173 |
0.5 ml |
Concentrate |
CE/IVD |
Z2701RS |
-
|
| Host |
Rabbit |
| Klon |
ZR173 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Pituitary |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG |
| Verdünnung |
Recombinant full-length human LHB protein |
| Lokalisation |
Cytoplasm, secreted |
LH
|
Zeta Corporation |
ZR173 |
0.1 ml |
Concentrate |
CE/IVD |
Z2701RT |
-
|
| Host |
Rabbit |
| Klon |
polyclonal |
| Format |
Concentrate |
| Reaktivität |
BV, CK, DG, FG, MS, PG, RB, RT |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Hodgkin´s Lymphoma, tonsil |
| Verdünnung |
1:100 |
| Isotyp |
Rabbit IgG |
| Verdünnung |
Synthetic peptide corresponding to human LMO2 protein |
| Lokalisation |
Nucleus |
LMO2
|
Zytomed Systems GmbH |
polyclonal |
0.5 ml |
Concentrate |
RUO |
512-17832 |
-
|
| Host |
Rabbit |
| Klon |
polyclonal |
| Format |
Concentrate |
| Reaktivität |
BV, CK, DG, FG, MS, PG, RB, RT |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Hodgkin´s Lymphoma, tonsil |
| Verdünnung |
1:100 |
| Isotyp |
Rabbit IgG |
| Verdünnung |
Synthetic peptide corresponding to human LMO2 protein |
| Lokalisation |
Nucleus |
LMO2
|
Zytomed Systems GmbH |
polyclonal |
1 ml |
Concentrate |
RUO |
512-17834 |
-
|
| Host |
Rabbit |
| Klon |
SP51 |
| Reaktivität |
BV,CK,DG,PG,RB,RT |
| Methode |
IHC-P, WB, FC |
| Vorbehandlung |
Citrate |
| Verdünnung |
1:100 |
LMO2
|
Zytomed Systems GmbH |
SP51 |
1 ml |
- |
RUO |
512-3514 |
-
|
| Host |
Rabbit |
| Klon |
ZR87 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Lymph Node |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG |
| Verdünnung |
Recombinant human LMO2 protein fragment (around aa 23-140) |
| Lokalisation |
Nucleus, Cytoplasm, Cell Membrane |
LMO2
|
Zeta Corporation |
ZR87 |
1 ml |
Concentrate |
CE/IVD |
Z2397RL |
-
|
| Host |
Rabbit |
| Klon |
ZR87 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Lymph Node |
| Verdünnung |
- |
| Isotyp |
IgG |
| Verdünnung |
Recombinant human LMO2 protein fragment (around aa 23-140) |
| Lokalisation |
Nucleus, Cytoplasm, Cell Membrane |
LMO2
|
Zeta Corporation |
ZR87 |
7 ml |
Concentrate |
CE/IVD |
Z2397RP |
-
|
| Host |
Rabbit |
| Klon |
ZR87 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Lymph Node |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG |
| Verdünnung |
Recombinant human LMO2 protein fragment (around aa 23-140) |
| Lokalisation |
Nucleus, Cytoplasm, Cell Membrane |
LMO2
|
Zeta Corporation |
ZR87 |
0.5 ml |
Concentrate |
CE/IVD |
Z2397RS |
-
|
| Host |
Rabbit |
| Klon |
ZR87 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Lymph Node |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG |
| Verdünnung |
Recombinant human LMO2 protein fragment (around aa 23-140) |
| Lokalisation |
Nucleus, Cytoplasm, Cell Membrane |
LMO2
|
Zeta Corporation |
ZR87 |
0.1 ml |
Concentrate |
CE/IVD |
Z2397RT |
-
|
| Host |
Rabbit |
| Klon |
polyclonal |
| Format |
Ready-to-use |
| Methode |
F, P |
| Positivkontrolle |
Tonsil |
| Verdünnung |
- |
| Isotyp |
Rabbit IgG |
| Lokalisation |
Cytoplasm |
Lysozyme
|
Diagnostic Biosystems |
polyclonal |
6 ml |
Ready-to-use |
CE/IVD |
PDR005 |
-
|
| Host |
Rabbit |
| Klon |
polyclonal |
| Format |
Concentrate |
| Methode |
F, P |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
Rabbit IgG |
| Lokalisation |
Cytoplasm |
Lysozyme
|
Diagnostic Biosystems |
polyclonal |
1 ml |
Concentrate |
CE/IVD |
RP028 |
-
|
| Host |
Rabbit |
| Klon |
polyclonal |
| Format |
Concentrate |
| Methode |
F, P |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
Rabbit IgG |
| Lokalisation |
Cytoplasm |
Lysozyme
|
Diagnostic Biosystems |
polyclonal |
0.1 ml |
Concentrate |
CE/IVD |
RP028-01 |
-
|
| Host |
Rabbit |
| Klon |
polyclonal |
| Format |
Concentrate |
| Methode |
F, P |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
Rabbit IgG |
| Lokalisation |
Cytoplasm |
Lysozyme
|
Diagnostic Biosystems |
polyclonal |
0.5 ml |
Concentrate |
CE/IVD |
RP028-05 |
-
|
| Host |
Monospecific Mouse |
| Klon |
ZM120 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Myeloid leukemia |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG2b /κ |
| Verdünnung |
Recombinant fragment of human Lysozyme protein (around aa 18-147) |
| Lokalisation |
Cytoplasm |
Lysozyme
|
Zeta Corporation |
ZM120 |
1 ml |
Concentrate |
CE/IVD |
Z2425ML |
-
|
| Host |
Monospecific Mouse |
| Klon |
ZM120 |
| Format |
Ready-to-use |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Myeloid leukemia |
| Verdünnung |
- |
| Isotyp |
IgG2b /κ |
| Verdünnung |
Recombinant fragment of human Lysozyme protein (around aa 18-147) |
| Lokalisation |
Cytoplasm |
Lysozyme
|
Zeta Corporation |
ZM120 |
7 ml |
Ready-to-use |
CE/IVD |
Z2425MP |
-
|
| Host |
Monospecific Mouse |
| Klon |
ZM120 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Myeloid leukemia |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG2b /κ |
| Verdünnung |
Recombinant fragment of human Lysozyme protein (around aa 18-147) |
| Lokalisation |
Cytoplasm |
Lysozyme
|
Zeta Corporation |
ZM120 |
0.5 ml |
Concentrate |
CE/IVD |
Z2425MS |
-
|
| Host |
Monospecific Mouse |
| Klon |
ZM120 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Myeloid leukemia |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG2b /κ |
| Verdünnung |
Recombinant fragment of human Lysozyme protein (around aa 18-147) |
| Lokalisation |
Cytoplasm |
Lysozyme
|
Zeta Corporation |
ZM120 |
0.1 ml |
Concentrate |
CE/IVD |
Z2425MT |
-
|
| Host |
Rabbit |
| Klon |
polyclonal |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Appendix |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
Rabbit IgG |
| Lokalisation |
Cytoplasm |
LYVE-1
|
Zytomed Systems GmbH |
polyclonal |
0.5 ml |
Concentrate |
RUO |
RBK014-05 |
-
|
| Host |
Rat |
| Klon |
MAC353 |
| Format |
TCS |
| Methode |
F, EL, IP |
| Isotyp |
Rat IgG2b |
| Verdünnung |
71 amino acid fusion protein corresponding to the C-terminal region of M31 |
M31 (Mouse)/ HP1 (Human)
|
Zytomed Systems GmbH |
MAC353 |
2 ml |
TCS |
RUO |
613-0003 |
-
|
| Host |
Mouse |
| Klon |
MAC387 |
| Format |
Purified |
| Methode |
F, P, FL |
| Vorbehandlung |
Trypsin |
| Positivkontrolle |
Human Spleen |
| Verdünnung |
1:100 - 1:200 (P) |
| Isotyp |
Mouse IgG1 |
| Verdünnung |
Human monocytes |
Macrophage
|
Zytomed Systems GmbH |
MAC387 |
200 µg |
Purified |
RUO |
613-0005 |
-
|
| Host |
Mouse |
| Klon |
MAC387 |
| Format |
Purified |
| Methode |
F, P, FL |
| Vorbehandlung |
Trypsin |
| Positivkontrolle |
Human Spleen |
| Verdünnung |
1:100 - 1:200 (P) |
| Isotyp |
Mouse IgG1 |
| Verdünnung |
Human monocytes |
Macrophage
|
Zytomed Systems GmbH |
MAC387 |
100 µg |
Purified |
RUO |
613-0006 |
-
|
| Host |
Mouse |
| Klon |
314G8 |
| Format |
Purified |
| Methode |
F, EL |
| Verdünnung |
1:25 : 1:200 (F) |
| Isotyp |
Mouse IgG1 |
| Verdünnung |
Recombinant soluble MadCAM-1-fc fusion protein |
MAdCAM-1 (Mucosal Addressin Cell Adhesion Molecule 1)
|
Zytomed Systems GmbH |
314G8 |
200 µg |
Purified |
RUO |
613-0019 |
-
|
| Host |
Rabbit |
| Klon |
polyclonal |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:200 |
| Isotyp |
Mouse IgG |
| Verdünnung |
Full length recombinant human MAGE-1 protein. |
| Lokalisation |
Cytoplasm |
MAGE-1
|
Zytomed Systems GmbH |
polyclonal |
1 ml |
Concentrate |
RUO |
513-4504 |
-
|
| Host |
Mouse |
| Klon |
304-1A5 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Normal or neoplastic breast tissue. |
| Verdünnung |
1:100 |
| Isotyp |
IgG1 /κ |
| Verdünnung |
Recombinant full-length protein |
| Lokalisation |
Cytoplasm |
Mammaglobin
|
Zeta Corporation |
304-1A5 |
1.0 ml |
Concentrate |
CE/IVD |
Z2007ML |
-
|
| Host |
Mouse |
| Klon |
304-1A5 |
| Format |
Ready-to-use |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Normal or neoplastic breast tissue. |
| Verdünnung |
- |
| Isotyp |
IgG1 /κ |
| Verdünnung |
Recombinant full-length protein |
| Lokalisation |
Cytoplasm |
Mammaglobin
|
Zeta Corporation |
304-1A5 |
7 ml |
Ready-to-use |
CE/IVD |
Z2007MP |
-
|
| Host |
Mouse |
| Klon |
304-1A5 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Normal or neoplastic breast tissue. |
| Verdünnung |
1:100 |
| Isotyp |
IgG1 /κ |
| Verdünnung |
Recombinant full-length protein |
| Lokalisation |
Cytoplasm |
Mammaglobin
|
Zeta Corporation |
304-1A5 |
0.5 ml |
Concentrate |
CE/IVD |
Z2007MS |
-
|
| Host |
Mouse |
| Klon |
304-1A5 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Normal or neoplastic breast tissue. |
| Verdünnung |
1:100 |
| Isotyp |
IgG1 /κ |
| Verdünnung |
Recombinant full-length protein |
| Lokalisation |
Cytoplasm |
Mammaglobin
|
Zeta Corporation |
304-1A5 |
0.1 ml |
Concentrate |
CE/IVD |
Z2007MT |
-
|
| Host |
Rabbit |
| Klon |
31A5 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Breast carcinoma. |
| Verdünnung |
1:100 |
| Isotyp |
IgG |
| Verdünnung |
Recombinant full-length protein |
| Lokalisation |
Cytoplasm |
Mammaglobin
|
Zeta Corporation |
31A5 |
1.0 ml |
Concentrate |
CE/IVD |
Z2009RL |
-
|
| Host |
Rabbit |
| Klon |
31A5 |
| Format |
Ready-to-use |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Breast carcinoma. |
| Verdünnung |
- |
| Isotyp |
IgG |
| Verdünnung |
Recombinant full-length protein |
| Lokalisation |
Cytoplasm |
Mammaglobin
|
Zeta Corporation |
31A5 |
7 ml |
Ready-to-use |
CE/IVD |
Z2009RP |
-
|
| Host |
Rabbit |
| Klon |
31A5 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Breast carcinoma. |
| Verdünnung |
1:100 |
| Isotyp |
IgG |
| Verdünnung |
Recombinant full-length protein |
| Lokalisation |
Cytoplasm |
Mammaglobin
|
Zeta Corporation |
31A5 |
0.5 ml |
Concentrate |
CE/IVD |
Z2009RS |
-
|
| Host |
Rabbit |
| Klon |
31A5 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Breast carcinoma. |
| Verdünnung |
1:100 |
| Isotyp |
IgG |
| Verdünnung |
Recombinant full-length protein |
| Lokalisation |
Cytoplasm |
Mammaglobin
|
Zeta Corporation |
31A5 |
0.1 ml |
Concentrate |
CE/IVD |
Z2009RT |
-
|
| Host |
Rabbit |
| Klon |
ZR363 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Normal or neoplastic breast tissue |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG |
| Verdünnung |
Recombinant full-length human Mammaglobin (SCGB2A2) protein |
| Lokalisation |
Cytoplasm |
Mammaglobin
|
Zeta Corporation |
ZR363 |
1 ml |
Concentrate |
CE/IVD |
Z2739RL |
-
|
| Host |
Rabbit |
| Klon |
ZR363 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Normal or neoplastic breast tissue |
| Verdünnung |
- |
| Isotyp |
IgG |
| Verdünnung |
Recombinant full-length human Mammaglobin (SCGB2A2) protein |
| Lokalisation |
Cytoplasm |
Mammaglobin
|
Zeta Corporation |
ZR363 |
7 ml |
Concentrate |
CE/IVD |
Z2739RP |
-
|
| Host |
Rabbit |
| Klon |
ZR363 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Normal or neoplastic breast tissue |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG |
| Verdünnung |
Recombinant full-length human Mammaglobin (SCGB2A2) protein |
| Lokalisation |
Cytoplasm |
Mammaglobin
|
Zeta Corporation |
ZR363 |
0.5 ml |
Concentrate |
CE/IVD |
Z2739RS |
-
|
| Host |
Rabbit |
| Klon |
ZR363 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Normal or neoplastic breast tissue |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG |
| Verdünnung |
Recombinant full-length human Mammaglobin (SCGB2A2) protein |
| Lokalisation |
Cytoplasm |
Mammaglobin
|
Zeta Corporation |
ZR363 |
0.1 ml |
Concentrate |
CE/IVD |
Z2739RT |
-
|
| Host |
Mouse and Rabbit |
| Klon |
304-1A5 & 31-A5 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Normal or neoplastic breast tissue. |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
Mouse IgG1/κ /Rabbit IgG |
| Verdünnung |
Recombinant full-length protein |
| Lokalisation |
Cytoplasm |
Mammaglobin Cocktail
|
Zeta Corporation |
304-1A5 & 31-A5 |
1.0 ml |
Concentrate |
CE/IVD |
Z2011MRL |
-
|
| Host |
Mouse and Rabbit |
| Klon |
304-1A5 & 31-A5 |
| Format |
Ready-to-use |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Normal or neoplastic breast tissue. |
| Verdünnung |
- |
| Isotyp |
Mouse IgG1/κ /Rabbit IgG |
| Verdünnung |
Recombinant full-length protein |
| Lokalisation |
Cytoplasm |
Mammaglobin Cocktail
|
Zeta Corporation |
304-1A5 & 31-A5 |
7 ml |
Ready-to-use |
CE/IVD |
Z2011MRP |
-
|